did-you-know? rent-now

Amazon no longer offers textbook rentals. We do!

did-you-know? rent-now

Amazon no longer offers textbook rentals. We do!

We're the #1 textbook rental company. Let us show you why.

9781859962442

Facioscapulohumeral Muscular Dystrophy (FSHD): Clinical Medicine and Molecular Cell Biology

by ;
  • ISBN13:

    9781859962442

  • ISBN10:

    1859962440

  • Edition: 1st
  • Format: Hardcover
  • Copyright: 2004-06-15
  • Publisher: Taylor & Franci

Note: Supplemental materials are not guaranteed with Rental or Used book purchases.

Purchase Benefits

List Price: $375.00 Save up to $189.37
  • Rent Book $236.25
    Add to Cart Free Shipping Icon Free Shipping

    TERM
    PRICE
    DUE
    USUALLY SHIPS IN 3-5 BUSINESS DAYS
    *This item is part of an exclusive publisher rental program and requires an additional convenience fee. This fee will be reflected in the shopping cart.

Supplemental Materials

What is included with this book?

Summary

Facioscapulohumeral muscular dystrophy (FSHD) is a genetic disorder involving slowly progressive muscle degeneration in which the muscles of the face, shoulder blades and upper arms are among the most severely affected. It is the third most common inherited muscular dystrophy, affecting 1 in 20,000. The search for the molecular basis of the disease is of interest to all genetic researchers, involving a deletion outside a coding region resulting in over-expression of adjacent genes. This volume summarizes the current understanding of the disorder, including clinical, molecular and therapeutic aspects.

Table of Contents

Abbreviations xv
Contributors xvii
Acknowledgements xx
Dedication xxi
Foreword xxiii
1. Introduction and overview of FSHD
1(16)
M. Upadhyaya and D.N. Cooper
Introduction
1(1)
Gene mapping studies
2(3)
DNA rearrangements associated with D4F10451 and D4Z4 repeats
2(2)
D424 repeats
4(1)
Sequence homology and genetic recombination between 4q35 and 10q26
5(1)
Somatic mosaicism
5(1)
The genotype/phenotype relationship in FSHD
6(1)
Gender bias
6(1)
Molecular diagnosis of FSHD
7(1)
FSHD muscle biochemistry and physiology
8(1)
The search for the FSHD gene
8(1)
Potential gene sequences within the FSHD candidate region
9(1)
Methylation studies
9(1)
Expression studies in the FSHD candidate region
10(1)
Therapy
10(1)
Possible disease mechanism
11(1)
Transcriptional derepression
11(1)
The FSHD enigma
12(1)
References
13(4)
2. Facioscapulohumeral muscular dystrophy: historical background and literature review
17(24)
M. Rogers
Historical aspects
17(3)
Clinical aspects
20(13)
Distribution of affected muscles
20(4)
Age of onset
24(1)
Penetrance
25(1)
Gender differences
26(1)
Hearing impairment
27(1)
Coats' disease and vascular retinopathy
28(2)
Cardiac involvement
30(2)
Early onset and rare features of FSHD
32(1)
Summary
33(1)
References
33(8)
3. Facioscapulohumeral muscular dystrophy: a clinician's experience
41(14)
G.W. Padberg
Historical notes
41(1)
Clinical picture
41(6)
Non-muscular features
47(1)
Infantile facioscapulohumeral muscular dystrophy
47(1)
Age at onset of the disease
48(1)
Gender and generation effects in FSHD
49(1)
Course of the disease
49(1)
Prevalence and fitness
50(1)
Penetrance
50(1)
Therapies
50(1)
References
51(4)
4. Mapping of the FSHD gene and the discovery of the pathognomonic deletion 55
R.R. Frants, L.A. Sandkuijl, S.M. van der Maarel and G.W. Padberg
Introduction
55(1)
Gene mapping prior to the advent of DNA polymorphisms
55(1)
Gene mapping with DNA polymorphisms
56(1)
Microsatellite markers; the first linkage success
57(1)
Probe p13E-11; the hallmark of FSHD success
57(1)
Rearrangement in de novo FSHD patients
58(1)
FSHD mutation caused by rearrangement of the 3.3 kb Kpnl repeat (D4Z4)
59(1)
Does the FSHD D4Z4 array modulate long-range gene expression?
59(1)
References
60(5)
5. Identification and characterization of candidate genes in FSHD region
65(20)
S. van Koningsbruggen, R.R. Frants, S.M. van der Maarel
Position effect as the underlying mechanism in FSHD
65(2)
The D4Z4 repeat and Dux4: the complete story?
67(1)
Gene search strategies in the FSHD candidate region
67(3)
Direct genomic analysis
68(1)
Exon trapping
69(1)
cDNA selection
70(1)
Direct sequence analysis
70(1)
The most promising candidate genes for FSHD
70(7)
FRG1, a tightly conserved nuclear protein
70(4)
TUBB4Q, a pseudogene?
74(1)
FRG2, a muscle-specific transcript
75(1)
ANTI, a muscle-specific mitochondrial protein
76(1)
Other candidate genes
77(1)
Concluding remarks
78(1)
References
78(7)
6. Evolution and structural organization of the homeobox-containing repeat D4Z4
85(12)
J.E. Hewitt
Introduction
85(1)
Organization of the D4Z4 repeat
85(2)
D4Z4-related sequences in the human genome
87(1)
Conservation of D4Z4 in other organisms
88(5)
D4Z4 orthologues in primates
88(1)
Further analysis of the evolution of D4Z4; the potential of genome sequence projects
89(4)
Conclusions
93(1)
References
93(4)
7. Subtelomeric exchange between 4q and 97 10q sequences
97(10)
R.R. Frants and S.M. van der Maarel
Introduction
97(1)
The second p13E-11 locus maps to 10g26
97(1)
Differential detection of the two loci
98(1)
'Cross-talk' between the subtelomeres of 4q and 10q
98(2)
Prevalence of interchromosomal exchange
100(1)
Repeat array configurations
101(1)
Functional consequences
102(1)
Repeat size distribution
102(1)
FSHD-sized repeat arrays
103(1)
References
104(3)
8. Genomic analysis of the subtelomeric regions of human chromosomes 10q and 4q: relevance to FSHD
107(10)
M. van Geel and J.E. Hewitt
Introduction
107(1)
Genomic analysis of the FSHD locus chromosome 4qter
107(1)
A polymorphism at the 4q telomere
108(1)
Extensive sequence homology between chromosomes 4qter and 10gter
108(3)
The 4q35 and 10g26 3.3 kb repeats
109(1)
Sequence homology between the 4q and 10q subtelomeres
110(1)
Sequence homology between chromosomes 4q35 and 10g26 extends proximal to the 3.3 kb repeats
111(1)
Relationship of 4qter to other telomeres
111(1)
Evolution of 4gter
111(2)
FSHD is only associated with the 4qA allele
113(1)
Concluding remarks
113(1)
References
114(3)
9. The DUX gene family and FSHD
117(18)
F. Coppée, C. Mattéotti, E. Ansseau, S. Sauvage, I. Leclercq, A. Leroy, A. Marcowycz, C. Gerbaux, D. Figlewicz, H. Ding and A. Belayew
Introduction
117(1)
Cloning of a gene promoter homologous to part of the D4Z4 unit
118(1)
Expression of double homeobox (DUX) genes located within 3.3 kb elements not linked to FSHD
119(2)
Expression in vivo of a DUX1 protein with properties of a transcription factor
121(1)
A putative DUX4 gene in the D4Z4 units of the FSHD locus
121(2)
Expression of the DUX4 protein
123(3)
A function for the DUX4 protein
126(1)
A putative DUX4c gene centromeric to D4Z4
126(3)
Discussion and conclusions
129(2)
References
131(4)
10. Facioscapulohumeral muscular dystrophy (FSHD): a disorder of muscle gene repression 135(16)
R. Tupler and D. Gabellini
Introduction
135(1)
D4Z4 contains heterochromatic elements
136(1)
The FSHD region on chromosome 4q35 contains genes and pseudogenes
137(1)
Haploinsufficiency of distal 4q does not cause facioscapulohumeral muscular dystrophy
138(1)
Expression of 4q35 genes is up-regulated in FSHD dystrophic muscle
138(1)
Detection of a nuclear activity that binds to D4Z4
139(2)
A new model for FSHD
141(2)
Open questions
143(1)
References
144(7)
11. Genotype-phenotype relationships in FSHD 151(18)
P. Lunt, M. Upadhyaya and M.C. Koch
Introduction
151(1)
What are the variations in phenotype and genotype against which any relationship between these can be gauged?
152(1)
Phenotypic parameters studied in FSHD
152(1)
Genotypic parameters against which the phenotypic parameters can be assessed
152(1)
Correlations and exceptions
153(2)
The broad correlations
153(1)
Emerging exceptions/cautions
154(1)
Null effects
154(1)
Unknowns
154(1)
Evidence for correlations
155(8)
Increasing clinical effect with reducing residual fragment size
155(1)
Infantile-onset cases and wider clinical effects
156(1)
Male:female difference
157(1)
New mutation and mosaicism
157(2)
Comparison of clinical and genetic properties between new mutation and familial cases
159(1)
Three categories of family presentation of FSHD (types I, II, III)
159(2)
Blnl-sensitive alleles and the type A and B polymorphism
161(1)
Emerging exceptions to the overall correlations
161(2)
Fitting severity variation and correlation with molecular models
163(2)
Proposed models
163(1)
Transcriptional derepression
164(1)
Understanding clinical variation in FSHD
164(1)
References
165(4)
12. Mosaicism and FSHD 169(16)
P.G.M. van Overveld, R.R. Frants and S.M. van der Maarel
Introduction
169(1)
Mosaicism explained
169(2)
Somatic mosaicism
171(1)
Germline mosaicism
172(1)
Somatic and germline mosaicism in FSHD
173(3)
Implications for genetic counseling and research
176(2)
Summary
178(2)
References
180(5)
13. Retinal vascular abnormalities in FSHD: a therapeutic message; clues to pathogenesis 185(12)
R.B. Fitzsimons
Introduction
185(1)
Retinal disease and FSHD
186(3)
Background and therapeutics
186(2)
Male sex bias in sporadic Coats' disease and in FSHD
188(1)
FSHD muscle and retinal diseases are both highly asymmetric
188(1)
Retinal disease and pathogenesis
189(2)
Norrie disease and Coats' disease can both be caused by mutation of a TGF-beta protein ('norrin')
189(2)
References
191(6)
14. Unusual clinical features associated with FSHD 197(14)
Y.K. Hayashi
Introduction
197(1)
Early-onset form of FSHD
197(1)
Unusual muscle involvement observed in FSHD patients
198(4)
Facial-sparing scapular myopathy
198(1)
Tongue atrophy
199(1)
Head drooping
199(1)
Abdominal muscle involvement and lumbar lordosis
199(2)
Limb girdle type muscle weakness
201(1)
Distal myopathy
201(1)
Muscle pain
202(1)
Association with other types of neuromuscular disorders
202(1)
Cardiac involvement
203(1)
Respiratory failure
203(1)
Central nervous system involvement
204(1)
Psychopathological and emotional examination
204(1)
Hearing loss
205(1)
Retinopathy
205(1)
References
206(5)
15. Molecular diagnosis of FSHD 211(24)
R.J.L.F. Lemmers, M.J.R. van derWeilen, E. Bakker and S. M. van der Maarel
Introduction
211(1)
General
212(1)
10g26 homology
212(1)
4;10 D4Z4 translocations
213(2)
Hybrid D4Z4 repeat arrays
215(1)
D4F10451 deletion
216(5)
Short non-pathogenic allels
221(1)
Mosaicism in FSHD
222(2)
Notl-digest for chromosomal assignment
224(1)
Bg/ll/Blnl dosage test
224(2)
Standard FSHD diagnostics
226(2)
DNA preparation
228(1)
Specificity and sensitivity
229(1)
Concluding remarks
229(1)
References
230(5)
16. FSHD myoblasts: in vitro studies 235(18)
D.A. Figlewicz, K. Barrett, A. Haefele Leskovar, J.R. Forrester, J.E. Sowden and R. Tawil
Introduction
235(1)
Myoblast morphology and replication
236(1)
Characterization of myoblasts
236(1)
Myoblast studies - cell biology
236(1)
Oxidative stress
237(2)
Cell survival studies in FSHD myoblasts
238(1)
Question of cell cycle/premature differentiation/premature senescence
239(7)
Intracellular redox state
239(2)
Senescence in FSHD myoblasts
241(1)
Cell cycle dysregulation/p21 detection in FSHD - a connection with oxidative stress?
241(4)
Senescence in FSHD myoblasts - replicative or premature
245(1)
Discussion/future directions
246(2)
References
248(5)
17. Exploring hypotheses about the molecular aetiology of FSHD: loss of heterochromatin spreading and other long-range interaction models 253(24)
M. Ehrlich
Introduction
253(2)
Background and complicating factors in studies of the molecular genetic aetiology of FSHD
255(5)
Large size of D4Z4 repeat array and associated FSHD candidate region and the importance of maintaining the natural spacing of FSHD-related DNA elements at 4q35
255(1)
Homology between 4q35 and 10g26
256(1)
Homology between the D4Z4 subregions and various chromosomes
257(1)
Homology between sequences proximal and distal to the D4Z4 array in 4g35/10g26 and various other chromosomal regions
258(1)
Tissue-specific and age-specific nature of the disease
259(1)
Molecular clues about genetic aspects of FSHD
260(2)
Difficulties with the PEV model for FSHD
262(2)
Other molecular genetic models for FSHD
264(5)
General considerations
264(1)
The long-distance looping for transcriptional activation in FSHD
265(4)
Conclusions
269(1)
References
270(7)
18. Histological, immunological, molecular and ultrastructural characteristics of FSHD muscle 277(22)
M.T. Rogers, M. Upadhyaya and C.A. Sewry
Introduction
277(1)
Patient characteristics
278(1)
Biopsy site
279(1)
Sample handling
279(2)
Immunoblotting (western blot) studies
281(1)
Ultrastructure
282(1)
Molecular analysis of FSHD
282(1)
Light microscopy
282(3)
Immunocytochemistry
285(2)
Electron microscopy
287(6)
Myofibrillar structure
287(1)
Mitochondria
288(2)
Basal lamina
290(1)
Glycogen
291(2)
Conclusion
293(1)
References
294(5)
19. Linkage analysis in non-chromosome 4-linked FSHD 299(10)
K. Bastress, J. Stajich, J. Gilbert and M. Speer
Introduction
299(1)
Facioscapulohumeral muscular dystrophy is genetically heterogeneous
299(2)
FSHD1B and FSHD1A are phenotypically indistinguishable
301(2)
Is FSHD1B allelic to other proximal myopathies?
303(1)
Status of linkage studies in FSHD1B
304(1)
Candidate gene studies in non-chromosome 4-linked FSHD
305(1)
Expression studies in FSHD1B
305(1)
Summary
306(1)
References
306(3)
20. Facioscapulohumeral muscular dystrophy: gender differences and genetic counselling in a complex disorder 309(16)
M. Manuela de Oliveira Tonini and M. Zatz
Introduction
309(1)
Abortive or asymptomatic cases
309(1)
Gender differences: reports from the premolecular era
310(1)
Gender differences following molecular analysis
311(1)
Recent analysis of a larger Brazilian sample
312(1)
Phenotypic severity versus fragment size
313(2)
Asymptomatic carriers
315(1)
Parental transmission
316(1)
Gender differences
316(1)
Clinical anticipation
317(1)
Is clinical anticipation influenced by the gender of the transmitting parent?
318(1)
How to relate clinical and genealogical observations and new molecular findings
319(1)
Genetic counselling and prenatal diagnosis
320(1)
References
321(4)
21. Genetic counselling for facioscapulohumeral muscular dystrophy (FSHD) 325(16)
P. Lunt
Introduction
325(2)
What are the common genetic situations and questions encountered in the genetic clinic in relation to FSHD?
327(2)
Patient themselves affected with FSHD (or affected child)
327(1)
Patient themselves affected with FSHD, or affected child or relative
328(1)
Specific genetic situations
329(8)
Typical classic familial case - known affected
329(2)
Typical dominant family history: consultand themselves clinically unaffected
331(3)
Mild presentation with or without a known family history
334(1)
Severe case in a relative (i.e. in a sib, or in other relative), or parents of a severely affected child (i.e. with same set of parents, or with new partner) or severe case in consultand
335(2)
References
337(4)
22. Sarcolemmal reorganization in FSHD 341(12)
P. Reed, N. C. Porter, J. Strong, P.W. Luther, K.M. Flanigan and R.J. Bloch
Introduction
341(1)
Sarcolemmal alterations in FSHD
342(3)
Sarcolemmal involvement in FSHD and other dystrophies
345(1)
Conclusion and model
346(2)
Future directives
348(1)
References
348(5)
23. Expression profiling in FSHD 353(18)
S.T. Winokur and Y.-W. Chen
Introduction
353(2)
Deletion of D4Z4 in FSHD
353(1)
Chromatin structure of D4Z4
354(1)
Regulation of gene expression
354(1)
Genome-wide expression profiling
355(1)
Overview
355(1)
Oligonucleotide arrays
355(1)
cDNA arrays
356(1)
Expression profiling of FSHD muscle
356(6)
Cell cycle and differentiation genes
356(2)
Common changes in muscular dystrophy
358(1)
Position effect vaiegation
359(1)
4q35 regional gene expression
360(2)
Myoblasts as models for differentiation
362(3)
Myogenesis
362(1)
Gene expression in FSHD myoblasts
362(1)
Protein expression in FSHD myoblasts
363(1)
Nuclear localization studies
364(1)
Summary
365(1)
References
366(5)
24. Therapeutic trials and medical management in FSHD 371(8)
R. Tawil and R.C. Griggs
Introduction
371(1)
Therapeutic trials in FSHD
372(2)
Corticosteroids
372(1)
Albuterol
372(1)
Creatinine monohydrate
373(1)
Medical management
374(1)
Assistive devices
374(1)
Surgical interventions
374(1)
Role of exercise
374(1)
Pain
375(1)
References
375(4)
Appendices 379(10)
Appendix I: The FSH Society
379(6)
Appendix II: The Muscular Dystrophy Campaign: pioneering research, providing care
385(2)
Appendix Ill: The Association Francaise contre les Myopathies
387(2)
Index 389

Supplemental Materials

What is included with this book?

The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.

The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.

Rewards Program